✦ LIBER ✦

High-dose idarubicin and busulphan as conditioning to autologous stem cell transplantation in adult patients with acute myeloid leukaemia

✍ Scribed by Felicetto Ferrara; Salvatore Palmieri; Mariacarla De Simone; Marco Sagristani; Assunta Viola; Barbara Pocali; Alfredo Fasanaro; Giuseppina Mele

Book ID: 108672971
Publisher: John Wiley and Sons
Year: 2005
Tongue: English
Weight: 138 KB
Volume: 128
Category: Article
ISSN: 0007-1048
DOI: 10.1111/j.1365-2141.2004.05303.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Continuous infusion idarubicin and intra

Continuous infusion idarubicin and intravenous busulphan as conditioning regimen to autologous stem cell transplantation for patients with acute myeloid leukaemia

✍ Felicetto Ferrara; Giuseppina Mele; Salvatore Palmieri; Mariangela Pedata; Carol 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 111 KB

## Abstract The current study aimed to evaluate the efficacy and toxicity of a combination of intravenous (iv) busulfan (Bu) and continuous infusion Idarubicin (IDA) as a conditioning regimen to autologous haematopoietic stem cell transplantation (ASCT) in patients with acute myeloid leukaemia (AML

Autologous stem cell transplantation for

Autologous stem cell transplantation for elderly patients with acute myeloid leukaemia conditioned with continuous infusion idarubicin and busulphan

✍ Felicetto Ferrara; Salvatore Palmieri; Mariangela Pedata; Assunta Viola; Tiziana 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 124 KB

## Abstract Different studies have suggested the potential utility of autologous stem cell transplantation (ASCT) in acute myeloid leukaemia (AML) of the elderly with encouraging results in selected patients. However, while the introduction of peripheral blood stem cells (PBSC) has consistently red

Gemtuzumab ozogamicin as maintenance the

Gemtuzumab ozogamicin as maintenance therapy after autologous stem cell transplantation in elderly patients with acute myeloid leukaemia

✍ Nicola Cascavilla; Giovanni D’Arena; Michele Mario Greco; Lorella Melillo; Emanu 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 55 KB

High-dose melphalan is an effective salv

High-dose melphalan is an effective salvage therapy in acute myeloid leukaemia patients with refractory relapse and relapse after autologous stem cell transplantation

✍ Gesine Bug; Johannes Atta; Stefan A. Klein; Bernd Hertenstein; Lothar Bergmann; 📂 Article 📅 2005 🏛 Springer 🌐 English ⚖ 107 KB

High-dose idarubicin, cyclophosphamide a

High-dose idarubicin, cyclophosphamide and melphalan as conditioning for autologous stem cell transplantation increases treatment-related mortality in patients with multiple myeloma: results of a randomised study

✍ R. Fenk; P. Schneider; M. Kropff; A. N. Huenerlituerkoglu; U. Steidl; C. Aul; B. 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 123 KB

Comparison of allogeneic stem cell trans

Comparison of allogeneic stem cell transplantation, high-dose cytarabine, and autologous peripheral stem cell transplantation as postremission treatment in patients with de novo acute myelogenous leukemia

✍ Apostolia-Maria Tsimberidou; Niki Stavroyianni; Nora Viniou; Maria Papaioannou; 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 148 KB 👁 2 views

## Abstract ## BACKGROUND Postremission therapy is critical in maintaining complete remission (CR) in patients with de novo acute myelogenous leukemia (AML). The aim of this trial was to compare allogeneic stem cell transplantation (SCT), high‐dose cytarabine (ara‐C; HiDAC), and autologous SCT as